An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: A real-life, long-term, follow-up, clinical practice in italy

Giuliano Tocci, Gianpiero Aimo, Dario Caputo, Carmine De Matteis, Tommaso Di Napoli, Antonino Granatelli, Pietro Lentini, Armando Magagna, Alfonso A. Matarrese, Davide Perona, Giuseppe Villa, Massimo Volpe

Research output: Contribution to journalArticlepeer-review


Introduction: The addition of the direct renin inhibitor aliskiren is demonstrated to improve blood pressure (BP) control rate and reduce progression of organ damage in treated hypertensive patients in clinical trials with a relatively short follow-up period. Aim: The objective of this study was to assess the effectiveness, safety and tolerability of aliskiren as an addon antihypertensive therapy in high-risk, treated, hypertensive patients, who were not controlled with concomitant treatment with at least two antihypertensive drugs under 'real-life' conditions, during a planned observation and treatment period of at least 12 months in Italy. Methods: Clinical data were derived from medical databases of treated, uncontrolled, hypertensive patients followed by specialized physicians operating in different clinical settings (hospital divisions or outpatient clinics) in Italy. Aliskiren was added to stable antihypertensive treatment, including at least two drug classes (independently of class or dosage) and unable to achieve BP control. Follow-up visits for measuring clinic BP levels and collecting data on drug safety and tolerability were planned at time intervals of 1, 6 and 12 months. At each predefined follow-up visit, aliskiren could be up-titrated from 150 to 300 mg daily if BP control was not achieved. Results: From May 2009 to June 2011, a total of 1186 treated, uncontrolled, hypertensive patients (46.3% female, aged 65.2 ± 11.7 years, mean duration of hypertension 13.2 ± 9.3 years, mean clinic BP levels 156.5 ± 15.9/90.3 ± 9.5mmHg) were enrolled. Systolic and diastolic BP levels were 141.1/82.4, 134.9/79.8 and 133.6/78.9 mmHg at 1-, 6- and 12-month follow-up visits, respectively (p <0.0001 vs baseline for all comparisons). These effects were consistent in all predefined subgroups, including those with left ventricular hypertrophy, renal disease, diabetes mellitus, coronary artery disease or cerebrovascular disease. Reduced levels of microalbuminuria were also reported, without affecting other renal and electrolyte parameters. Overall, compliance to study medication was high (93.0%), with a very low proportion of patients experiencing adverse events leading to drug discontinuation (3.6%). Conclusions: In this observational, prospective, open-label, multicentre study, we reported the 12-month clinical effectiveness, safety and tolerability of adding aliskiren to treated, uncontrolled, hypertensive patients in a 'real-life' setting in Italy. This strategy leads to a significantly improved BP control rate and low incidence of drug-related side effects or discontinuations.

Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number2
Publication statusPublished - 2012


  • aliskiren
  • antihypertensive therapy
  • direct renin inhibitors
  • high blood pressure
  • Hypertension
  • renin-angiotensin system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine


Dive into the research topics of 'An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: A real-life, long-term, follow-up, clinical practice in italy'. Together they form a unique fingerprint.

Cite this